Alcimed presentation

Press Release

The organ allocation process in the United States

Alcimed, an innovation & new business consulting firm, discusses current obstacles in the regulation of organ allocation in the United States with a brief look into potential innovative solutions, such as blockchain, in tackling some of these challenges.

Hydrogen for steel production: myth or reality?

The energetic properties of the hydrogen molecule are mainly known in the automotive industry for their use in fuel cells. But a much less widespread and equally promising application is the use of hydrogen in industrial processes, particularly in the steel industry, as a substitute for natural gas or other carbon fuels. Alcimed, a consulting company specializing in innovation and the development of new markets, is studying the potential of hydrogen in the steel industry and reviewing the current industrial approaches in this field.

Fibre optics: the ideal sensor for monitoring in extreme conditions

The use of optical fibre for more than 20 years in the telecommunications industry has made a significant contribution to reducing the cost and improving the quality of components. This evolution has led to the development of a new type of application: fibre optic sensors, a particularly interesting technology in extreme conditions where the conventional electrical sensors are missing. Alcimed, a consulting company specializing in innovation and new businesses, reviews the functioning and benefits of these sensors.

Plastic cars- the reality of tomorrow?

With increasingly stringent CO2 emission reduction targets imposed by the European Union, manufacturers must keep pace. The first possible solution is the electrification of the automotive fleet. The second is the reduction of the weight of combustion vehicles to lower their emissions. Substituting metal parts with plastic or composite parts could lead to substantial weight savings. In terms of their properties, these materials reach the same level of performance as metals, but then why are our vehicles still mainly made of metal? ALCIMED, a consulting company specializing in innovation and the development of new markets, provides an overview of the use of plastic materials in the automotive industry and the obstacles to their widespread use.

Total Lab Automation: an opportunity for the in vitro diagnostics industry?

In response to the needs of streamlined processes and increased productivity, the use of Total Lab Automation (TLA) systems is massively increasing in medical biology laboratories. Alcimed, a consulting company specializing in innovation and new businesses, set out to highlight the potential of these workflow automation systems and question the related prospects for actors in vitro diagnostics.

Paediatric drugs, a continuing need

13 December 2018, In December 2006, the European Parliament adopted the Regulation on medicinal products for paediatric use aiming to stimulate pharmaceutical companies to develop medicinal forms intended for children. The European Medicines Agency (EMA) has been noting a significant increase in the number of new paediatric drugs; nevertheless, there is still a genuine need in this area. In fact, today, more than 50% of paediatric prescriptions are for off-label uses. Alcimed, an innovation and new business consulting firm, examined the factors that still limit the development of paediatric drugs, 10 years after the law was introduced.

Emergence of serious games for neurodegenerative diseases Which business models in France?

Although research is constantly moving forward, many neurodegenerative diseases remain poorly understood and grey areas still persist. Consequently, with the low number of effective drug treatments, new disease management methods are being developed. One of these methods is the serious games, alias “serious video games”, which are games developed to have a therapeutic effect. Just imagine if, after a doctor’s appointment, you found video game sessions on your prescription. Alcimed, a consulting company specializing in innovation and new businesses, set out to further explore this trend, which could radically impact current patient care.

Smartphone recycling: A sector of excellence in the making

French consumers change their mobile phones every other year. These devices have significant impacts on the environment. Rather than keeping our old smartphones in our drawers, solutions exist to give old smartphones a second life to avoid keeping them in a drawer. Alcimed reviews how the smartphone valorization chain is gradually being implemented.

The CAR-T cell revolution: The funding puzzle

With impressive results, particularly where conventional treatments have failed, CAR-T cells represent a real revolution in onco-hematology care. Two treatments are already available in the United States and are about to arrive in Europe. Alcimed, a consulting company specialized in innovation and the new businesses, has investigated this expensive therapy whose next challenge is undeniably its financing.

Blue light: a new target for the cosmetics industry

Considered as an effective treatment against acne or premature skin ageing, blue light is subject to debate and is now the new priority of the cosmetics industry. From benefits to negative effects on our skin, Alcimed, an innovation consulting company, reviews the usage of blue light in cosmetic skin care products

HAPPY AGEING: A new concept in the cosmetics industry to further penetrate the elderly care market

The elderly represent a high-potential target for the cosmetics industry. The share of the population aged 60 or over will increase by a factor of 2.5 by 2050 to reach 33% of the world's population. Moreover, the buying power of the elderly remains high, and they are more inclined to consume as they are driven by the desire to enjoy a new life after the age of 60. After targeting the elderly with anti-ageing products for a long time, cosmetics manufacturers wish to seduce them with the concept of "happy ageing" or "ageing well". What are the scientific claims behind happy ageing? Which brands are positioned on this concept and what products do they offer? Alcimed, an innovation consulting company, studies this new strategy of the cosmetics industry.

Four tailor-made cosmetics manufacturing strategies From artisanal point-of-sale manufacturing to automated small batch production

Following the enthusiasm for cosmetics and tailor-made care, Alcimed, a consulting firm specialized in innovation and new businesses, is taking a closer look at the strategies and technologies implemented by four French and Canadian cosmetic brands to produce these products in small series in order to meet the needs of a diverse community of consumers.

Access to healthcare in Africa: challenges and innovations

On the occasion of World Africa Day on May 25, Alcimed, a consulting firm specializing in innovation and the development of new markets, is revisiting the issue of access to healthcare in Africa. Access to treatments for infectious diseases (HIV, hepatitis B and C, malaria, tuberculosis, etc.) remains a challenge in Africa. Awareness of non-communicable diseases (heart attacks, stroke, cancer, COPD, etc.) is on the rise, and represents a novel challenge.

Plastic bottles with a bright future

Alcimed, a consulting company specializing in innovation and the development of new markets, offers an overview of key innovation trends in the field of PET plastic bottles for beverages.

How to assess whether a raw material is really becoming critical?

It’s a fact: the French and global industrial sector is heavily depending on many raw materials to ensure its digital transformation and energy transition. How do we anticipate the future supply chain for rare metals, monopolistic raw materials, and metals with very low reserves? ALCIMED, an innovation and new business consulting firm, has reviewed the criteria impacting the criticality assessment of a raw material.

Oral delivery of macromolecules: Big Pharma keep searching for the Holy Grail

Representing 9 out of the top 10 income-generating products on the market, biological drugs are now undoubtedly the main growth driver for the pharmaceutical industry. Big Pharma are looking not only to expand their portfolio with new macromolecules, but also to differentiate by offering delivery routes less invasive than injection for their blockbuster products. Oral delivery, long considered to be the Holy Grail, has been investigated for that objective for several years. How do market players position themselves in this race? Alcimed, an innovation and new business consulting firm, explores past and present challenges of these developments.

Alzheimer’s: towards new modalities of care

Alzheimer is the most common neurodegenerative disease and is a source of great concern within our society. Currently, patients suffering from the condition are routinely treated with four drugs (and their generics). However, since August 1st 2018, after being deemed ineffective by the High Authority of Health (HAS), these drugs are no longer reimbursed in France. This decision, unique on a European scale, raises the question about care management of the 900,000 patients concerned1. The non-medicinal care available now, provides better support for patients, but the situation highlights the increased need to accelerate research to develop new curative molecules.

5 key trends in managing respiratory diseases

With more than 200 million patients suffering from Chronic Obstructive Pulmonary Disease (COPD), 235 million asthmatics, and 8.7 million patients affected by tuberculosis, respiratory diseases are gaining ground worldwide. Given these numbers and the impact on patients' quality of life, manufacturers are looking for innovations that could improve patient care. Alcimed, a consulting company specialized in innovation and new businesses, looked into the 5 key trends that will define the future of respiratory disease management.

Observations and evolution prospects for the PAERPA program within the frame of PTAs implementation.

Since 2016, the French Ministry of Social Affairs and Health has been rolling out their PAERPA program in one pilot territory per region, aiming at improving care for the ageing population and preventing the loss of its autonomy. Alcimed has supported several territories in the implementation of this program, both on the formalization of management procedures and on more operational aspects, capitalizing on the results of innovative actions carried out in the first pilot territories. The firm is now sharing its insight on the conditions for a successful roll-out and on the prospects of the PAERPA program in the context of the PTAs (Territorial Support Platforms) implementation.

Preventive biology: definition and challenges

Alcimed, a consulting company specialized in innovation and new businesses, provides an update on the on the definition and challenges of preventive biology. As an integral part of "anti-aging" medicine it brings together applications at the frontiers of medicine and early diagnosis, sometimes incorporating controversial practices.

Gene-editing: What’s next after CRISPR Cas9?

Alcimed, an innovation and new business consulting firm, is committed to supporting the pharmaceutical industry in observing emerging technologies such as gene editing technologies CRISPR Cas9 and the following generations.

Hydrogen, vector of energy transition

Hydrogen, applied for the first time in the field of aerospace, particularly in the Apollo Program, is now invading our daily lives. The many initiatives around this promising energy vector and the creation of the International Hydrogen Council in 2017 (around the French groups Air Liquide, Alstom, Engie and Total) are clear signs that the hydrogen revolution is in motion. Its high energy efficiency and storage capacities position hydrogen as a substitute for fossil fuels and as an integrator of renewable energies.

Medically assisted procreation: What are the future challenges for ART and IVF centers in France?

In response to societal demands for the availability of vitrification of oocytes and access to Assisted Reproductive Technologies (ART) for all women, the French Government has initiated national discussions that could potentially lead to evolutions in the context of medically assisted reproduction in France. Beyond the related ethical issues, a different type of challenge is emerging for ART and IVF (In vitro fertilization) centers: how to organize themselves to meet the increasing demand? Alcimed, a consulting company specialized in innovation and new business perspectives looked into the key future challenges lying ahead of these centers.

Lightweight and flexible cells, a new horizon for solar energy!

Lightweight and flexible photovoltaic solutions are continuously being developed. Numerous projects are emerging, mainly due to increasing yields and falling prices. These technologies are opening the door to new applications which were otherwise inaccessible with heavy and rigid panels. ALCIMED, a consulting firm specialized in innovation and new businesses, reviewed this technological (r)evolution that is opening doors to a world of new photovoltaic applications!

Natural and organic cosmetics: 5 unusual plants to rejuvenate the skin

While the global cosmetics market is growing steadily with annual growth rates of around 3.5%, natural and organic cosmetics seem to be doing even better with a projected annual rate reaching 10%. Plants have become an essential beauty ally, inviting themselves into the formulations of our cosmetic products. But beyond plant products that we traditionally find in our cosmetic departments such as aloe vera, shea butter, or argan oil, relying on the latest advances in research in herbal medicine, today's products appreciate the unknown plants with amazing properties. Alcimed, a consulting company specialized in innovation and new businesses, offers insights into these plants and the benefits they bring.

Alzheimer’s: Reaching the cure within this generation

Alcimed, an innovation and new business consulting firm, remains committed to supporting the pharmaceutical industry in untangling the complex web of difficulties behind curing Alzheimer’s, a disease with one of the highest drug clinical trial failure rates.